Business
OncBioMune Awaits Approval from Regulatory Committee to Commence Phase 2 Trial of ProscaVax as Front Line Prostate Cancer Treatment
OncBioMune Awaits Approval from Regulatory Committee to Commence Phase 2 Trial of ProscaVax as Front Line Prostate Cancer Treatment.
About this update from Theralink Technologies Inc.
[{"type":"text","content":"\nOncBioMune Awaits Approval from Regulatory Committee to Commence Phase 2 Trial of ProscaVax as Front Line Prostate Cancer Treatment\n\nOncBioMune Awaits Approval from Regulatory Committee to Commence Phase 2 Trial of ProscaVax as Front Line Prostate Cancer Treatment\n\nBATON ROUGE, LA--(Marketwired - August 31, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (\"OncBioMune\" or the \"Company\"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, a proprietary cancer vaccine technology and commercialization of a portfolio of products internationally, is pleased to report that the protocol for the planned Phase 2 study of ProscaVax for early-stage prostate cancer is now under review by the Regulatory Committee at Beth Israel Deaconess Medical Center/Harvard Medical School, the host hospital network for the study.In the trial, ProscaVax, OncBioMune's novel immunotherapeutic cancer vaccine consisting of a combination of tumor-associated prostate specific antigen (PSA) with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF), will be evaluated for safety, tolerability and efficacy in treatment-naïve prostate cancer patients at disease presentation. Per the protocol, patients to be enrolled in the study will be newly diagnosed with prostate cancer, deciding in collaboration with their oncologist to forego standard approved therapies, such as a radical prostatectomy, radiation or brachytherapy, in favor of careful monitoring for disease progression, a process known more commonly as \"active surveillance.\" Presently, there are no FDA-approved treatments for prostate cancer patients in active surveillance.\"The Regulatory Committee is a component of the Institutional Review Board and integral to the protocol approval process to commence the study,\" commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. \"I interpret the protocol now being in their hands as a signal that we are getting close to conducting the first ever trial of ProscaVax as a front-line treatment for prostate cancer.\"Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/. About OncBioMune Pharmaceuticals, Inc.OncBioMune Pharmaceuticals is a revenue-stage biopharmaceutical company engaged in the development of novel canc...